Published on 12.03.2021
Hope for a treatment for nephronophthisis (NPH), a severe pediatric ciliopathy
The ciliopathies are a large family of genetic diseases. One of them, nephronophthisis, is the leading genetic cause of end-stage renal disease in children and young adults. Today, without curative treatment, patients suffer rapid deterioration of kidney function, but also irreversible damage to the retina and/or growth and cognitive deficits. The medical stakes related to this pathology are therefore high.
The founders of Medetia, Jean-Philippe Annereau and Luis Briseno-Roa, have been particularly involved in the field of ciliopathies and nephronophthisis for the last 5 years and have the objective to develop therapeutic molecules and wish to focus their efforts on a first lead molecule, MDT-110. This molecule has been validated at the level of a preclinical cell model in vitro (loss of the cell cilium), and in vivo in a mouse model mimicking the pathology, patented in 2017, as a result of research works conducted by the "molecular basis of inherited renal diseases" laboratory led by Dr. Sophie Saunier, Inserm Research Director (Institut Imagine Inserm U1163 / University of Paris). Medetia is targeting possible therapeutic trials from 2024.
The medico-economic interest is protected by an exclusive license agreement for the use of MDT-110 in renal ciliopathies negotiated and signed by Inserm Transfert on behalf of INSERM, IHU Imagine, Université de Paris and Medetia.
Medetia is located near the patients, in the heart of Hôpital Necker-Enfants malades AP-HP
Medetia is located in Paris in Institut Imagine - labeled IHU and Carnot Institute -, and collaborates with the laboratory of Dr Sophie Saunier, who identified half of the genes responsible for nephronophthisis and co-discovered the lead molecule. Medetia is also a partner in the RHU (University Hospital Research, Programme d'Investissements d'Avenir) C'IL-LICO project "Medicine of the future for ciliopathies with renal impairment", coordinated by the IHU Imagine and bringing together 5 research centers on biomarkers and the identification of patients with nephronophthisis.
Medetia benefits from a dynamic of institutional and private support
Alongside Institut Imagine, many partners, institutions and financiers believe in the project. Inserm Transfert is also supporting the project and has enabled Medetia to benefit from the support of the HHSF (Human Health Startup Factory) consortium, coordinated by Inserm Transfert, which has accredited Medetia's project for its innovative and DeepTech character. This labeling has enabled the company to complete a recent seed fundraising through grants and the issuance of convertible bonds via the French Tech program (Emergence and Seed) orchestrated by Bpifrance.
Medetia has been included in the Challenges media's "100 start-ups to invest in in 2021" in the Medtech and Biotech category.
Medetia inserts artificial intelligence into an innovative collaborative platform
Medetia was the first start-up to be hosted on the Imagine Institute's Lab-in-labs platform, which allows it to benefit from unique expertise and preclinical models on ciliopathies affecting the kidney, eyes or heart, all in one place. In return, Medetia brings AI-assisted research for the quantification of renal lesions at the cellular level on microscopy tests with Perkin-Elmer, on histological sections with QuantaCell and for the design of new chemical compounds optimized by artificial intelligence with Iktos.
Learn more about Imagine’s Lab-in-labs
Learn more about Medetia
Learn more about Inserm Transfert